Quarterly ResultMay 14, 2026, 04:13 PM
Arcadia Biosciences Q1 Net Loss $4.4M; Revenue Down 8%
AI Summary
Arcadia Biosciences reported a net loss of $4.4 million for the first quarter of 2026, a significant decrease from a net income of $2.6 million in Q1 2025. Total revenues declined 8% to $1.1 million, primarily due to a revenue reserve release in the prior year, despite an 18% increase in Zola coconut water volumes. The company achieved its lowest SG&A expenses in its history, generated $2.1 million from preferred investment option exercises, and plans a new product launch this fall.
Key Highlights
- Net loss attributable to common stockholders was $4.4 million, down from $2.6 million net income in Q1 2025.
- Total revenues decreased 8% to $1.1 million in Q1 2026 from $1.2 million in Q1 2025.
- Zola coconut water volumes increased 18% year-over-year.
- Selling, general, and administrative expenses decreased by $559,000 to the lowest level in company history.
- Generated approximately $2.1 million in gross proceeds from the exercise of preferred investment options.
- Cash and cash equivalents increased to $954,000 as of March 31, 2026, from $259,000 at year-end 2025.
- Company expects to launch a new product this fall.